The number of lipid droplets and the areas of steatosis and macrovascular steatosis were significantly decreased by 26.0–49.8% in the MP-treated Lep KO mice compared to the vehicle-treated Lep KO mice, without any difference in their non-alcoholic fatty liver disease (NAFLD) scores. Here, LEP is linked to metabolic dysfunction-associated steatotic liver disease.